Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 713519, 6 pages
http://dx.doi.org/10.1155/2013/713519
Clinical Study

Interferon Alpha Association with Neuromyelitis Optica

1Department of Neurology, Vejle Hospital, 7100 Vejle, Denmark
2Institute of Molecular Medicine, University of Southern Denmark, J.B. Winsloewsvej 19,3, 5000 Odense C, Denmark
3Institute of Regional Health Research, University of Southern Denmark, 29 Sdr. Boulevard, 5000 Odense C, Denmark
4Department of Rheumatology, Odense University Hospital, Winsloewsvej 19B, 2., 5000 Odense C, Denmark
5Department of Biostatistics, University of Southern Denmark, 29 Sdr. Boulevard, 5000 Odense C, Denmark
6Odense Patient Data Explorative Network, Odense University Hospital, Soenderjyllands, Hospital, Egelund 10, 6200 Aabenraa, Denmark
7The Multiple Sclerosis Clinic of Southern Jutland, Vejle, Esbjerg, Soenderborg, Denmark
8Department of Neurology, Sønderborg Hospital, Denmark
9Department of Clinical Immunology, Odense University Hospital, Denmark

Received 21 August 2013; Revised 9 October 2013; Accepted 11 October 2013

Academic Editor: D. Craig Hooper

Copyright © 2013 Nasrin Asgari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Lassmann, “Targeting intracerebral inflammation in multiple sclerosis: is it feasible?” Acta Neuropathol, vol. 124, no. 3, pp. 395–396, 2012. View at Google Scholar
  2. C. F. Lucchinetti, R. N. Mandler, D. McGavern et al., “A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica,” Brain, vol. 125, part 7, pp. 1450–1461, 2002. View at Google Scholar · View at Scopus
  3. V. A. Lennon, T. J. Kryzer, S. J. Pittock, A. S. Verkman, and S. R. Hinson, “IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel,” Journal of Experimental Medicine, vol. 202, no. 4, pp. 473–477, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Asgari, R. Khorooshi, S. T. Lillevang, and T. Owens, “Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid,” Journal of Neuroimmunology, vol. 254, no. 1-2, pp. 76–82, 2013. View at Google Scholar
  5. N. Asgari, T. Owens, J. Frøkiær, E. Stenager, S. T. Lillevang, and K. O. Kyvik, “Neuromyelitis optica (NMO)—an autoimmune disease of the central nervous system (CNS),” Acta Neurologica Scandinavica, vol. 123, no. 6, pp. 369–384, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. E. N. Benveniste and H. Qin, “Type I interferons as anti-inflammatory mediators,” Science Signaling, vol. 2007, no. 416, article pe70, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. B. G. Arnason, “Immunologic therapy of multiple sclerosis,” Annual Review of Medicine, vol. 50, pp. 291–302, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Teige, A. Treschow, A. Teige et al., “IFN-β gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis,” Journal of Immunology, vol. 170, no. 9, pp. 4776–4784, 2003. View at Google Scholar · View at Scopus
  9. M. Prinz, H. Schmidt, A. Mildner et al., “Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system,” Immunity, vol. 28, no. 5, pp. 675–686, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. H. Kim, W. Kim, X. F. Li, I. J. Jung, and H. J. Kim, “Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?” Multiple Sclerosis Journal, vol. 18, no. 10, pp. 1480–1483, 2012. View at Google Scholar
  11. M. Tanaka, K. Tanaka, and M. Komori, “Interferon-β1b treatment in neuromyelitis optica,” European Neurology, vol. 62, no. 3, pp. 167–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Khorooshi, A. Wlodarczyk, N. Asgari, and T. Owens, “Neuromyelitis optica-like pathology is dependent on type I interferon response,” Experimental Neurology, vol. 247, pp. 744–747, 2013. View at Publisher · View at Google Scholar
  13. N. Asgari, S. T. Lillevang, H. P. B. Skejoe, M. Falah, E. Stenager, and K. O. Kyvik, “A population-based study of neuromyelitis optica in Caucasians,” Neurology, vol. 76, no. 18, pp. 1589–1595, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. D. M. Wingerchuk, V. A. Lennon, S. J. Pittock, C. F. Lucchinetti, and B. G. Weinshenker, “Revised diagnostic criteria for neuromyelitis optica,” Neurology, vol. 66, no. 10, pp. 1485–1489, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Asgari, C. Nielsen, E. Stenager, K. O. Kyvik, and S. T. Lillevang, “HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica,” Multiple Sclerosis, vol. 18, no. 1, pp. 23–30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. W. I. McDonald, A. Compston, G. Edan et al., “Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis,” Annals of Neurology, vol. 50, no. 1, pp. 121–127, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Barkhof, M. Filippi, D. H. Miller et al., “Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis,” Brain, vol. 120, part 11, pp. 2059–2069, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at Google Scholar · View at Scopus
  19. S. Jarius, J. Frederikson, P. Waters et al., “Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis,” Journal of the Neurological Sciences, vol. 298, no. 1-2, pp. 158–162, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. E. C. Borden, G. C. Sen, G. Uze et al., “Interferons at age 50: past, current and future impact on biomedicine,” Nature Reviews Drug Discovery, vol. 6, no. 12, pp. 975–990, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. N. Theofilopoulos, R. Baccala, B. Beutler, and D. H. Kono, “Type I interferons (α/β) in immunity and autoimmunity,” Annual Review of Immunology, vol. 23, pp. 307–336, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. L. B. Ivashkiv, “Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis,” Autoimmunity, vol. 36, no. 8, pp. 473–479, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Banchereau and V. Pascual, “Type I interferon in systemic lupus erythematosus and Other autoimmune diseases,” Immunity, vol. 25, no. 3, pp. 383–392, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. F. A. Y. Borg and D. A. Isenberg, “Syndromes and complications of interferon therapy,” Current Opinion in Rheumatology, vol. 19, no. 1, pp. 61–66, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Bitsch, A. Dressel, K. Meier et al., “Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b,” Journal of Neurology, vol. 251, no. 12, pp. 1498–1501, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Durelli, B. Ferrero, A. Oggero et al., “Autoimmune events during interferon beta-1b treatment for multiple sclerosis,” Journal of the Neurological Sciences, vol. 162, no. 1, pp. 74–83, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Yamasaki, K. Matsumoto, Y. Takahashi, H. Nakanishi, Y. Kawai, and M. Miyamura, “Case of NMO (neuromyelitis optica) spectum disorder triggered by interferon alpha, which involved extensive pyramidal tract lesion of the brain,” Rinsho Shinkeigaku, vol. 52, no. 1, pp. 19–24, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. S. F. Roemer, J. E. Parisi, V. A. Lennon et al., “Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis,” Brain, vol. 130, part 5, pp. 1194–1205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Ishizu, M. Osoegawa, F. J. Mei et al., “Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis,” Brain, vol. 128, part 5, pp. 988–1002, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Içöz, E. Tüzün, M. Kürtüncü et al., “Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients,” International Journal of Neuroscience, vol. 120, no. 1, pp. 71–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. X. Feng, N. P. Reder, M. Yanamandala et al., “Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis,” Journal of the Neurological Sciences, vol. 313, no. 1-2, pp. 48–53, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Palace, M. I. Leite, A. Nairne, and A. Vincent, “Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers,” Archives of Neurology, vol. 67, no. 8, pp. 1016–1017, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. R. C. Axtell, B. A. de Jong, K. Boniface et al., “T helper type 1 and 17 cells determine efficacy of interferon-Β in multiple sclerosis and experimental encephalomyelitis,” Nature Medicine, vol. 16, no. 4, pp. 406–412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. B. G. Weinshenker, D. M. Wingerchuk, S. J. Pittock, C. F. Lucchinetti, and V. A. Lennon, “NMO-IgG: a specific biomarker for neuromyelitis optica,” Disease Markers, vol. 22, no. 4, pp. 197–206, 2006. View at Google Scholar · View at Scopus